These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25733960)

  • 1. Ethical and public policy challenges for pharmacogenomics.
    Gershon ES; Alliey-Rodriguez N; Grennan K
    Dialogues Clin Neurosci; 2014 Dec; 16(4):567-74. PubMed ID: 25733960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.
    Morley KI; Hall WD
    J Mol Med (Berl); 2004 Jan; 82(1):21-30. PubMed ID: 14598045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic data sample collection and storage: ethical issues and policy approaches.
    Joly Y; Knoppers BM
    Pharmacogenomics; 2006 Mar; 7(2):219-26. PubMed ID: 16515401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ethical and legal overview of pharmacogenomics: perspectives and issues.
    Sillon G; Joly Y; Feldman S; Avard D
    Med Law; 2008 Dec; 27(4):843-57. PubMed ID: 19202860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics, ethics, and public policy.
    Peterson-Iyer K
    Kennedy Inst Ethics J; 2008 Mar; 18(1):35-56. PubMed ID: 18561577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ethics, politics, and rights in pharmacogenomics].
    Bellver Capella V
    Rev Derecho Genoma Hum; 2002; (17):31-55. PubMed ID: 12703107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications.
    Garrison LP; Carlson RJ; Carlson JJ; Kuszler PC; Meckley LM; Veenstra DL
    Drug Metab Rev; 2008; 40(2):377-401. PubMed ID: 18464050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics: bridging the gap between science and practice.
    Lee KC; Ma JD; Kuo GM
    J Am Pharm Assoc (2003); 2010; 50(1):e1-14; quiz e15-7. PubMed ID: 20368146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and pharmacogenomics: recent developments, their clinical relevance and some ethical, social, and legal implications.
    Norbert PW; Roses AD
    J Mol Med (Berl); 2003 Mar; 81(3):135-40. PubMed ID: 12755119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymmetry in scientific method and limits to cross-disciplinary dialogue: toward a shared language and science policy in pharmacogenomics and human disease genetics.
    Ozdemir V; Williams-Jones B; Graham JE; Preskorn SH; Gripeos D; Glatt SJ; Friis RH; Reist C; Szabo S; Lohr JB; Someya T
    J Investig Med; 2007 Apr; 55(3):130-41. PubMed ID: 17481382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhetoric and hype: where's the 'ethics' in pharmacogenomics?
    Williams-Jones B; Corrigan OP
    Am J Pharmacogenomics; 2003; 3(6):375-83. PubMed ID: 14672518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Informed consent in the context of pharmacogenomic research: ethical considerations.
    Howard HC; Joly Y; Avard D; Laplante N; Phillips M; Tardif JC
    Pharmacogenomics J; 2011 Jun; 11(3):155-61. PubMed ID: 21445091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics and children: meeting the ethical challenges.
    Freund CL; Clayton EW
    Am J Pharmacogenomics; 2003; 3(6):399-404. PubMed ID: 14672521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada.
    Bashir NS; Ungar WJ
    Genome; 2015 Dec; 58(12):527-40. PubMed ID: 26623513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethics and policy perspectives on personalized medicine in the post-genomic era.
    Landon MR
    J Biolaw Bus; 2005; 8(3):28-36. PubMed ID: 16459425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ethical, Legal and Regulatory Issues Associated with Pharmacogenomics: Systematically Quantifying the Literature.
    Hewitt JE
    J Law Med; 2018 Apr; 25(3):782-793. PubMed ID: 29978667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics: questions and concerns.
    Mahlknecht U; Voelter-Mahlknecht S
    Curr Med Res Opin; 2005 Jul; 21(7):1041-7. PubMed ID: 16004671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ethics of pharmacogenomics.
    Neil D; Craigie J
    Monash Bioeth Rev; 2004 Apr; 23(2):9-20. PubMed ID: 15810202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racializing drug design: implications of pharmacogenomics for health disparities.
    Lee SS
    Am J Public Health; 2005 Dec; 95(12):2133-8. PubMed ID: 16257939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics.
    van Delden J; Bolt I; Kalis A; Derijks J; Leufkens H
    Bioethics; 2004 Aug; 18(4):303-21. PubMed ID: 15449404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.